Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx ® reinforcing sustained efficacy and safety profile in psoriasis
Novartis, a global leader in Immunology &Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis. Data will be presented at a key medical congress in the second half of 2017.
To the Editor: Racial/ethnic differences in general health care utilization exist in the United States.1 Little is known about health care utilization among racial/ethnic groups for skin diseases, including for psoriasis, the most prevalent immune-mediated disease.2 We aimed to evaluate health care utilization for psoriasis by race/ethnicity using population-based data derived from the Medical Expenditure Panel Surveys, the most complete source of information on health care utilization, cost, and health insurance coverage in the United States.
The link between the metabolic syndrome (MetS) and skin diseases is increasingly important, with new associations being discovered. The association between MetS and psoriasis or MetS and hidradenitis suppurativa is well known, although the relationship between MetS and various autoimmune or inflammatory diseases has only recently attracted interest. Some inflammatory skin diseases, such as vitiligo, scleredema, recurrent aphthous stomatitis, Beh çet disease, rosacea, necrobiosis lipoidica, granuloma annulare, skin tags, knuckle pads, and eruptive xanthomas, have possible associations with MetS.
The cutaneous manifestations of obesity and the associated metabolic syndrome (MetS) may present with a wide variety of cutaneous findings, including acanthosis nigricans, acrochordon, cellulitis, psoriasis, hidradenitis suppurativa, acne, and hirsutism. Being aware of such clinical signs and the underlying systemic disorders may facilitate earlier diagnoses, thereby permitting earlier of therapy initiation and prevention of long-term sequelae. In this process, dermatologists are key figures in the early detection of MetS and its clinical manifestations.
The association of the metabolic syndrome (MetS) and its components with immune-mediated chronic inflammatory disorders has attracted much interest within the last two decades. In addition to the well-established association of psoriasis with MetS, recent data point to an association between MetS and hidradenitis suppurativa, as well. The association of hidradenitis suppurativa with MetS and its components, such as diabetes, obesity, and dyslipidemia, has been consistently identified in controlled studies.
Chronic plaque psoriasis is an immune-mediated inflammatory skin disease that is strongly associated with the clinical features of the metabolic syndrome (MetS), including abdominal obesity, hypertension, atherogenic dyslipidemia, type 2 diabetes, insulin resistance, and nonalcoholic fatty liver disease. The strength of these associations has been repeatedly confirmed by several observational studies. In particular, the prevalence of MetS in patients with psoriasis ranges from 20% to 50%, with a risk of having MetS is at least double in psoriatic patients compared with nonpsoriatic control individuals.
The metabolic syndrome —otherwise called syndrome X, insulin resistance syndrome, Reaven syndrome, and “the deadly quartet”—is the name given to the aggregate of clinical conditions comprising central and abdominal obesity, systemic hypertension, insulin resistance (or type 2 diabetes mellitus), and atherogenic dy slipidemia. It is a prothrombotic and proinflammatory state characterized by increased inflammatory cytokine activity. In addition to inflammatory dermatoses such as psoriasis, lichen planus, and hidradenitis suppurativa, metabolic syndrome is also commonly associated with accelerated athe...
The metabolic syndrome (MetS), also termed syndrome X, the deadly quartet, and insulin resistance syndrome, has been of interest for many years; however, there has been a striking increase in the prevalence of MetS over the last few decades, coinciding with the global epidemic of obesity and diabetes mellitus.1,2 MetS is a constellation of several clinical and laboratory findings that have been reported to be associated with numerous medical and dermatologic conditions, such as psoriasis, hidradenitis suppurativa, and acne vulgaris; moreover, the severity of psoriasis is significantly associated with MetS at higher psorias...
The concept of psoriasis as a systemic disease might be considered an innovation of the 21st century, although more than 100 years ago, L. Duncan Bulkley (1845-1928), a New York dermatologist, alluded to the systemic nature of psoriasis.1 Louis A Duhring (1845-1913), pathfinder for American dermatology, titled his partially completed encyclopedia of skin disease Cutaneous Medicine,2 indicating that many skin diseases are more than “skin deep” in their manifestations.
Background: Psoriasis is an immune-mediated, inflammatory disease. Adipokines contribute to the regulation of immune-mediated processes and inflammation.Objective: The aim of our study was to systematically review the literature for studies that have evaluated the circulating concentrations of adipokines in patients with psoriasis and controls and to meta-analyze the best evidence available.Methods: Eligible were studies that have assessed leptin, resistin, or adiponectin concentrations in psoriatic patients and a reference group. The study was conducted in adherence with the PRISMA standards.Results: Psoriatic patients ha...
The British Association of Dermatologists provides evidence-based recommendations on the use of biologic therapies for the treatment of psoriasis and psoriatic arthritis in adults and children.The British Journal of Dermatology